

PROTAC BRD4 Degradar-8 Biochemical

PROTAC BRD4 Degradar-8

CATALOG #
AAA227181


PRODUCT SYNONYMS

PROTAC BRD4 Degradar-8; PROTAC BRD4 Degradar-8 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	DMSO: 90 mg/mL (81.65 mM), Need ultrasonic <1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTAC BRD4 Degradar-8 (compound 8; 6 days) inhibits the proliferation of PC3 prostate cancer cells, with an IC ₅₀ of 28 nM[1]. PROTAC BRD4 Degradar-8 (4 h) suppresses MYC gene transcript in MV4-11 AML cells, with an IC ₅₀ of 11 nM[1]. PROTAC BRD4 Degradar-8 (4 h) potently degrades the BRD4 protein in PC3 prostate cancer cells, with an DC ₅₀ of 7.5 nM[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
MPC-0767, CAS 1310540-32-9



Structure
MPC-0767, CAS 1310540-32-9

ADDITIONAL INFORMATION

Related Product Information for PROTAC BRD4 Degradar-8 biochemical	PROTAC BRD4 Degradar-8 is a potent BRD4 inhibitor, with IC ₅₀ s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degradar-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells[1].
References	1. Se-Ho Kim, et al. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5254-7.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

